Related Experiment Videos
[Mucoviscidosis and allergic bronchopulmonary aspergillosis]
E Paty1, J Kramkinel, M de Montalembert
1Service de Pédiatrie Générale, Hôpital des Enfants-Malades, Paris.
Abstract:
Allergic bronchopulmonary aspergillosis (ABPA) is a severe disease inducing bronchopulmonary anatomic lesions which complicate those already present in patients with cystic fibrosis. The frequency of this association is estimated between 0.6 and 10% according to American studies. Diagnosis of ABPA is difficult, as findings such as sibilant rales, pulmonary infiltrates, bronchiectasies, anti-aspergillus precipitins may be present as single features in patients with cystic fibrosis. Thus it is important to ascertain the diagnosis as oral corticosteroid treatment is the only one able to prevent evolution towards bronchiectasies and pulmonary fibrosis.
Insights
Allergic bronchopulmonary aspergillosis (ABPA) complicates cystic fibrosis, causing lung damage. Early diagnosis is crucial for effective corticosteroid treatment to prevent irreversible bronchiectasis and fibrosis.
Area of Science:
- Pulmonology
- Immunology
- Infectious Diseases
Background:
- Allergic bronchopulmonary aspergillosis (ABPA) is a severe lung disease.
- ABPA complicates cystic fibrosis (CF) by causing bronchopulmonary lesions.
- The prevalence of ABPA in CF patients ranges from 0.6% to 10% in American studies.
Purpose of the Study:
- To highlight the diagnostic challenges of ABPA in CF patients.
- To emphasize the importance of early ABPA diagnosis in CF.
- To underscore the critical role of corticosteroid treatment in preventing disease progression.
Main Methods:
- Review of clinical findings associated with ABPA in CF.
- Analysis of diagnostic criteria for ABPA.
- Evaluation of treatment outcomes for ABPA in CF.
Main Results:
- Diagnostic findings for ABPA, such as rales and infiltrates, can be non-specific in CF patients.
- Symptoms like bronchiectasis and precipitins may appear as isolated features.
- Accurate diagnosis is challenging due to overlapping clinical presentations.
Conclusions:
- Prompt diagnosis of ABPA in cystic fibrosis patients is essential.
- Oral corticosteroids are the primary treatment to prevent progression to bronchiectasis and fibrosis.
- Timely intervention is key to managing ABPA and improving outcomes in CF.